References
- Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. The STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR*Trial). Am J Cardiol 2003; 92: 152–60
- Clark JM, Brancati FL, Diehl AME. Non-alcoholic fatty liver disease: the most common cause of abnormal liver enzymes in the US population. Gastroenterology 2001;120 Suppl a-65: Abstract.
- Angulo P, Lindor KD. Non-alcoholic fatty liver disease. Gastroenterol Hepatol 2002;17 Suppl: 186–90.
- Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. J Med 1999; 107: 450–5
- Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 137–45
- Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21: 27–41
- Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, et al. Hepatic cytochrome P450 2E1 activity in non-diabetic patients with nonalcoholic steatohepatitis. Hepatology 2003; 37: 544–50
- Emery MG, Fisher JM, Chien JY, Kharasch ED, Dellinger EP, Kowdley KV, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003; 38: 428–35
- Chen Q, Galleano M, Cederbaum AI. Cytotoxicity and apoptosis produced by arachidonic acid in HepG2 cells overexpressing human cytochrome P-4502E1. Alcohol Clin Exp Res 1998; 22: 782–4
- Kessova I, Cederbaum AI. CYP2E1: biochemistry, toxicology, regulation and function in ethanol-induced liver injury. Curr Mol Med 2003; 3: 509–18